145 related articles for article (PubMed ID: 38287621)
1. Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure.
Arends S; de Wolff L; van Nimwegen JF; Verstappen GMPJ; Vehof J; Bombardieri M; Bowman SJ; Pontarini E; Baer AN; Nys M; Gottenberg JE; Felten R; Ray N; Vissink A; Kroese FGM; Bootsma H
Lancet Rheumatol; 2021 Aug; 3(8):e553-e562. PubMed ID: 38287621
[TBL] [Abstract][Full Text] [Related]
2. Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study).
van Nimwegen JF; Mossel E; van Zuiden GS; Wijnsma RF; Delli K; Stel AJ; van der Vegt B; Haacke EA; Olie L; Los LI; Verstappen GM; Pringle SA; Spijkervet FKL; Kroese FGM; Vissink A; Arends S; Bootsma H
Lancet Rheumatol; 2020 Mar; 2(3):e153-e163. PubMed ID: 38263653
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abatacept in active primary Sjögren's syndrome: results of a phase III, randomised, placebo-controlled trial.
Baer AN; Gottenberg JE; St Clair EW; Sumida T; Takeuchi T; Seror R; Foulks G; Nys M; Mukherjee S; Wong R; Ray N; Bootsma H
Ann Rheum Dis; 2021 Mar; 80(3):339-348. PubMed ID: 33168545
[TBL] [Abstract][Full Text] [Related]
4. Long-term abatacept treatment for 48 weeks in patients with primary Sjögren's syndrome: The open-label extension phase of the ASAP-III trial.
de Wolff L; van Nimwegen JF; Mossel E; van Zuiden GS; Stel AJ; Majoor KI; Olie L; Los LI; Vissink A; Spijkervet FKL; Verstappen GMPJ; Kroese FGM; Arends S; Bootsma H
Semin Arthritis Rheum; 2022 Apr; 53():151955. PubMed ID: 35091325
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
[TBL] [Abstract][Full Text] [Related]
6. Development and performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), consisting of frequently active clinical domains, in two randomised controlled trials in primary Sjögren's syndrome.
de Wolff L; Arends S; Pontarini E; Bombardieri M; Bowman SJ; Bootsma H
Clin Exp Rheumatol; 2021; 39 Suppl 133(6):100-106. PubMed ID: 34796851
[TBL] [Abstract][Full Text] [Related]
7. Qualitative Research with Patients and Physicians to Assess Content Validity and Meaningful Change on ESSDAI and ESSPRI in Sjögren's.
Cooper C; Wratten S; Williams-Hall R; Bookman AAM; Ndife B; Hueber W; Goswami P
Rheumatol Ther; 2022 Dec; 9(6):1499-1515. PubMed ID: 36114443
[TBL] [Abstract][Full Text] [Related]
8. Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial.
van der Heijden EHM; Blokland SLM; Hillen MR; Lopes APP; van Vliet-Moret FM; Rosenberg AJWP; Janssen NG; Welsing PMJ; Iannizzotto V; Tao W; Pandit A; Barone F; Kruize AA; Radstake TRDJ; van Roon JAG
Lancet Rheumatol; 2020 May; 2(5):e260-e269. PubMed ID: 38273473
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T; Kaul M; Szántó A; Tseng JC; Papas AS; Pylvaenaeinen I; Hanser M; Abdallah N; Grioni A; Santos Da Costa A; Ferrero E; Gergely P; Hillenbrand R; Avrameas A; Cenni B; Siegel RM
Ann Rheum Dis; 2024 Feb; 83(3):360-371. PubMed ID: 37932009
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward Sjögren's syndrome Endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks.
Tsuboi H; Matsumoto I; Hagiwara S; Hirota T; Takahashi H; Ebe H; Yokosawa M; Hagiya C; Asashima H; Takai C; Miki H; Umeda N; Kondo Y; Ogishima H; Suzuki T; Hirata S; Saito K; Tanaka Y; Horai Y; Nakamura H; Kawakami A; Sumida T
Mod Rheumatol; 2015 Mar; 25(2):187-93. PubMed ID: 25211401
[TBL] [Abstract][Full Text] [Related]
12. Abatacept ameliorates both glandular and extraglandular involvements in patients with Sjögren's syndrome associated with rheumatoid arthritis: Findings from an open-label, multicentre, 1-year, prospective study: The ROSE (Rheumatoid Arthritis with Orencia Trial Toward Sjögren's Syndrome Endocrinopathy) and ROSE II trials.
Tsuboi H; Toko H; Honda F; Abe S; Takahashi H; Yagishita M; Hagiwara S; Ohyama A; Kondo Y; Nakano K; Tanaka Y; Shimizu T; Nakamura H; Kawakami A; Fujieda Y; Atsumi T; Suzuki Y; Kawano M; Nishina N; Kaneko Y; Takeuchi T; Kobayashi H; Takei M; Ogasawara M; Tamura N; Takasaki Y; Yokota K; Akiyama Y; Mimura T; Murakami K; Mimori T; Ohshima S; Azuma N; Sano H; Nishiyama S; Matsumoto I; Sumida T
Mod Rheumatol; 2023 Jan; 33(1):160-168. PubMed ID: 35134994
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of abatacept for patients with Sjögren's syndrome associated with rheumatoid arthritis. An open label, multicenter, one-year, prospective study: ROSE (Rheumatoid Arthritis with Orencia Trial toward Sjögren's syndrome Endocrinopathy) trial.
Tsuboi H; Matsumoto I; Hagiwara S; Hirota T; Takahashi H; Ebe H; Yokosawa M; Yagishita M; Takahashi H; Kurata I; Ohyama A; Honda F; Asashima H; Miki H; Umeda N; Kondo Y; Hirata S; Saito K; Tanaka Y; Horai Y; Nakamura H; Kawakami A; Sumida T
Mod Rheumatol; 2016 Nov; 26(6):891-899. PubMed ID: 27459020
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of abatacept for the treatment of patients with primary Sjögren's syndrome.
Machado AC; Dos Santos LC; Fidelix T; Lekwitch I; Soares SB; Gasparini AF; Augusto JV; Junior NC; Trevisani VFM
Clin Rheumatol; 2020 Jan; 39(1):243-248. PubMed ID: 31420813
[TBL] [Abstract][Full Text] [Related]
15. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
16. Development and preliminary validation of the Sjögren's Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren's syndrome.
Seror R; Baron G; Camus M; Cornec D; Perrodeau E; Bowman SJ; Bombardieri M; Bootsma H; Gottenberg JE; Fisher B; Hueber W; van Roon JA; Devauchelle-Pensec V; Gergely P; Mariette X; Porcher R; ;
Ann Rheum Dis; 2022 Jul; 81(7):979-989. PubMed ID: 35393271
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
Fisher BA; Szanto A; Ng WF; Bombardieri M; Posch MG; Papas AS; Farag AM; Daikeler T; Bannert B; Kyburz D; Kivitz AJ; Carsons SE; Isenberg DA; Barone F; Bowman SJ; Espié P; Floch D; Dupuy C; Ren X; Faerber PM; Wright AM; Hockey HU; Rotte M; Milojevic J; Avrameas A; Valentin MA; Rush JS; Gergely P
Lancet Rheumatol; 2020 Mar; 2(3):e142-e152. PubMed ID: 38263652
[TBL] [Abstract][Full Text] [Related]
18. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial.
Felten R; Devauchelle-Pensec V; Seror R; Duffau P; Saadoun D; Hachulla E; Pierre Yves H; Salliot C; Perdriger A; Morel J; Mékinian A; Vittecoq O; Berthelot JM; Dernis E; Le Guern V; Dieudé P; Larroche C; Richez C; Martin T; Zarnitsky C; Blaison G; Kieffer P; Maurier F; Dellal A; Rist S; Andres E; Contis A; Chatelus E; Sordet C; Sibilia J; Arnold C; Tawk MY; Aberkane O; Holterbach L; Cacoub P; Saraux A; Mariette X; Meyer N; Gottenberg JE
Ann Rheum Dis; 2021 Mar; 80(3):329-338. PubMed ID: 33208345
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of iguratimod on patients with primary Sjögren's syndrome: a randomized, placebo-controlled clinical trial.
Shao Q; Wang S; Jiang H; Liu L
Scand J Rheumatol; 2021 Mar; 50(2):143-152. PubMed ID: 33118847
[No Abstract] [Full Text] [Related]
[Next] [New Search]
